Nestle India Q4FY23 results preview- Net profit to jump 20%, sales growth continues on volume, pricing
时间:2024-06-26 10:14:26 阅读(143)
Kickstarting the earnings season for the FMCG sector, Nestle India is expected to maintain strong growth momentum with net profit jumping as high as 20.7 per cent on-year for the fourth quarter of FY2023. The FMCG major had recorded net profit of Rs 628.06 crore in the previous quarter of FY23, and Rs 594.71 crore for the fourth quarter of FY22. Nestle India is estimated to record a sales growth in double digits, in the range of 11.7- 14.5 per cent, led by a mix of volume and pricing growth.
“Nestlé India is expected to maintain strong growth momentum with 12.8 per cent sales growth led by a mix of volume and pricing growth. Maggi noodles and chocolate categories are expected to grow at faster pace but milk and related product categories to see moderate sales given high milk prices are adversely impacting growth,” said ICICI Securities. Nestle India is due to announce its January-March quarter results on Tuesday, April 25. The company follows a January to December accounting year.
According to brokerage firms and analysts, gross margins at Nestle India are expected to contract due to inflation in key input prices. “Gross margins to contract by 89 bps YoY, due to inflation in key input prices. EBITDA margins expected to contract by 58 bps YoY at 22.8 per cent. EBITDA expected to grow by 11.6 per cent, while PAT to grow by 13.2 per c
上一篇:Nifty’s intraday charts show weakness, uptrend possible above 16700; Buy ITC, Bharti Airtel stocks
(The stock recommendations in this story are by the respective research analysts and brokerage firms. FinancialExpress.com does not bear any responsibility for their investment advice. Capital markets investments are subject to rules and regulations. Please consult your investment advisor before investing.)
猜你喜欢
- Buy Bajaj Holdings and Zee stocks for gains while Nifty 50 faces resistance near 17521 and 17563
- Budget 2024 expectation- Govt’s stance on AI – Will govt’s ‘AI push’ be visible in Budget document-
- Blue Moon 2023- Stunning images of rare super blue Moon illuminate the sky across globe – Take a look
- Nifty to move towards all-time high or bears to drag index below 18400- Key things to know before market opens
- Nifty to reclaim 18300 or sink further- Check US stocks, Asian markets, FII activity, SGX Nifty, more
- Nifty witnessing extreme volatility, could retest 17800 resistance; Timken among stocks to buy
- Bourses give nod for transfer of NCDs from HDFC Ltd to HDFC Bank
- Tiruchirappalli International Airport update- PM Modi unveils Rs 1,100 crore state-of-the-art terminal building – Check photos here
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.